期刊文献+

新辅助化疗对直肠癌手术的影响 被引量:2

Impact of Neo-adjuvant Chemotherapy on the Efficacy of Operation for Rectal carcinoma
原文传递
导出
摘要 为探讨新辅助化疗对直肠癌手术的影响,并比较FOI,FOX4方案和5-FU/LV方案在直肠癌新辅助化疗中的效果。本研究采用随机对照研究方法,将2006年5月至2010年5月我院收治的拟行手术治疗的67例直肠癌患者随机分为A、B、C组,A组21例患者术前接受FOL FOX4方案化疗,B组22例患者术前接受5-FU/LV方案化疗,C组24例患者在完善术前检查、排除手术禁忌症后即行手术治疗,对比分析A、B组化疗前后肿块临床触诊情况、直肠镜检评价情况,以及三组手术情况和术后复发情况。结果显示,化疗2个周期后,A组完全缓解(cR)1例,部分缓解(PR)11例,疾病稳定(SD)9例;B组CR0例,PR13例,SD9例,两组总有效率(CR+PR)比较差异无统计学意义,P〉0.05。A、B、C组保肛术后分别复发1例(4.8%)、1例(4.5%)和3例(12.5%)。A、B组与C组相比,复发率差异均有统计学意义,P〈0.05;A、B组差异无统计学意义,P〉0.05。三组术后切口感染、吻合口漏发生率差异无统计学意义,P〉0.05。结果表明,FOI。FOX4方案和5-FU/LV方案行新辅助化疗均可缩小直肠原发肿瘤,且不增加术后并发症发生率,效果满意,但两者效果无明显差异。 The objective of this study was to investigate the influence of neo-adjuvant chemotherapy on the efficacy of operation for rectal carcinoma, and compare the efficacies of FOLFOX4 schema and 5-FU/LV schema,by using random control method. In this study 67 rectal carcinoma patients admitted from May, 2006 yr. to May,2010 yr. in author's hospital were randomly divided into three groups:A,B,C group;A group( n =21) was subject to FOLFOX4 schema,B group( n =22) to 5-FU/LV schema, preoperatively, while C group( n = 24) just received operation once following preoperative examination and excepting operative contraindication; and,the following items of the 3 groups were compared and analysed, including the clinical palpation and rectoscopy status on neoplasm mass before and after chemotherapy,and the operative and postoperative recurrence status. As results,after two cycles of chemotherapy in A group,one case was CR, 11 cases PR, 9 cases SD; in B group, respectively 0 case, 13 cases, 9 cases; between the total effective rates(CR+PR) of two groups there was no statistical difference( P 〉0.05). After anus-preserved procedure recurrence case numbers in A, B, C group was 1 (4.8 %), 1 (4.5 %), 3 ( 12.5 % ) respectively; C group was compared with A group, and with B group in recurrence rate there was statistical difference( P〈0.05) ,but there was no statistical difference between A and B groups( P 〉0.05). In incidences of wound infection,stoma leakage there was no statistical difference among the three groups( P 〉0.05). Results show that performing FOLFOX4 and 5-FU/LV schema's neo-adjuvant chemotherapy can all decrease primary neoplasms of rectum, and does not increase postoperative incidence of complication with satisfactory outcome;but the efficacy two schemas do not have significant difference.
作者 胡凌 唐迎春
出处 《中国肛肠病杂志》 2011年第12期16-18,共3页 Chinese Journal of Coloproctology
关键词 直肠癌 新辅助化疗 FOLFOX4方案 5-FU/LV方案 疗效 Rectal carcinoma Neo-adjuvant chemotherapy FOLFOX4 schema 5-FU/LV schema Thera-peutic effect
  • 相关文献

参考文献10

  • 1吴阶平 裘法祖.黄家驷外科学[M].北京:人民卫生出版社,2002,1.2307.
  • 2Valentini V,Coco C,Cellini N,et al. Preoperative chemora diation with cisplatin and 5 fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys, 1999,45 (5) : 1175- 1184.
  • 3Matsushita D, Kitazono M, Baba K, et al. A case of ad vanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemo- therapy. Gan To Kagaku Ryoho,2010,37(1):173-176.
  • 4郁宝铭.进一步提高直肠癌疗效的策略[J].中华肿瘤防治杂志,2007,14(2):81-84. 被引量:10
  • 5郁宝铭,王吉甫.胃肠外科学.北京:人民卫生出版社,2000.1109-1126.
  • 6高友这下,沈浩.直肠癌术后生活质量研究现状和进展[J].中国肛肠病杂志,2001,21(4):40-42. 被引量:62
  • 7宫媛,吴本俨,苏斌斌.272例直肠癌患者的预后影响因素分析[J].解放军医学杂志,2008,33(5):608-610. 被引量:28
  • 8Sauer R, Becket H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med,2004,351(17):1731- 1710.
  • 9Julien I,A,Thorson AG. Current neoadjuvant strategies in rectal cancer.,J Surg Oncol,2010,101(4):321 326.
  • 10Castaldo ET, Parikh AA, Pinson CW, el al. Improvement of survival with response to neoadjuwmt radiation therapy for rectal cancer. Arch Surg,2009,144(2) : 129- 135.

二级参考文献38

共引文献132

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部